Rizatriptan: Difference between revisions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Auto-created stub |
MDElliottMD (talk | contribs) parser-claude: Rizatriptan MedTemplate refill, Top 300 stub upgrade |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic = Rizatriptan | | generic = Rizatriptan (benzoate) | ||
| brand = Maxalt | | brand = Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) | ||
| classes = Triptan, | | structure = | ||
| mechanism = 5-HT1B/ | | classes = [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]], [[:Category:Antimigraine medicines|Antimigraine medicine]], [[:Category:Analgesics|Analgesic]] | ||
| uses = <vote slug="acute-migraine-use">Acute migraine with or without aura (FDA; adult and pediatric ages 6+)</vote> | |||
| starting_dose = 5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours | |||
| preparations = Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg | |||
| fda_max = 30 mg/24 hours | |||
| pill_id = | |||
| routes = Oral | |||
| onset = 30 minutes for migraine relief | |||
| duration = 4-6 hours; headache recurrence is common | |||
| halflife = 2-3 hours<ref name="maxalt-label">FDA Prescribing Information, Maxalt (rizatriptan benzoate), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020864s022,020865s024lbl.pdf</ref> | |||
| bioavailability = ~45% (oral; substantially higher than sumatriptan's ~14%)<ref name="maxalt-label" /> | |||
| pregnancy = Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US | |||
| mechanism = <vote slug="rizatriptan-mech-claim">Selective 5-HT1B and 5-HT1D receptor agonist (the triptan-class signature). Compared to sumatriptan, oral bioavailability is substantially higher (~45% vs ~14%) and onset is faster, with similar headache-recurrence rates. The 5-HT1B effect produces cranial vasoconstriction reversing the neurogenic vasodilation of migraine; the 5-HT1D effect inhibits CGRP release at trigeminal nerve terminals.</vote> '''Propranolol substantially raises rizatriptan exposure''' (~70% increase) via MAO-A inhibition of rizatriptan metabolism; the 5 mg dose is required when used with propranolol. Same triptan-class contraindications: coronary artery disease, vasospastic angina, uncontrolled hypertension, ischemic stroke history, hemiplegic or basilar migraine<ref name="maxalt-label" />. | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Triptans]] | |||
[[Category:Antimigraine medicines]] | |||
[[Category:Analgesics]] | [[Category:Analgesics]] | ||
Latest revision as of 07:22, 23 May 2026
Rizatriptan (benzoate)
Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours
Preparations
Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg
US FDA Max
30 mg/24 hours
Pharmacology
Routes
Oral
Onset
30 minutes for migraine relief
Duration
4-6 hours; headache recurrence is common
Half-life
2-3 hours[1]
Bioavailability
~45% (oral; substantially higher than sumatriptan's ~14%)[1]
Pregnancy
Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Selective 5-HT1B and 5-HT1D receptor agonist (the triptan-class signature). Compared to sumatriptan, oral bioavailability is substantially higher (~45% vs ~14%) and onset is faster, with similar headache-recurrence rates. The 5-HT1B effect produces cranial vasoconstriction reversing the neurogenic vasodilation of migraine; the 5-HT1D effect inhibits CGRP release at trigeminal nerve terminals.0 Propranolol substantially raises rizatriptan exposure (~70% increase) via MAO-A inhibition of rizatriptan metabolism; the 5 mg dose is required when used with propranolol. Same triptan-class contraindications: coronary artery disease, vasospastic angina, uncontrolled hypertension, ischemic stroke history, hemiplegic or basilar migraine[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Maxalt (rizatriptan benzoate), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020864s022,020865s024lbl.pdf